June 17, 2024 07:28 AM EDTUpdated 01:06 PM
R&D

Up­dat­ed: Take­da’s Ovid-li­censed drug fails two Phase 3 epilep­sy stud­ies

Kyle LaHucik

Senior Reporter

Max Bayer

Pharma Reporter

Take­da’s en­zyme ther­a­py soti­cle­stat, which aims to bal­ance brain cho­les­terol and re­duce seizures, failed two Phase 3 tri­als in cer­tain forms …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

A service from the Financial Times